Sucroferric oxyhydroxide monotherapy for hyperphosphatemia in Indian chronic kidney disease patients undergoing hemodialysis: A phase IV, single-arm, open-label study
This first real-world study in Indian CKD patients on hemodialysis shows SO as a safe, and effective monotherapy for HP, though its small sample size limits generalizability.
Authors
- Pramod P. Wangikar (ORCID: https://orcid.org/0000-0003-0108-7585)
- M R Niranjan
- Anil Kumar Bhalla (ORCID: https://orcid.org/0000-0003-4998-9385)
- Sanjay Srinivasa
- Vibhanshu Gupta
- Sachin R. Suryawanshi (ORCID: https://orcid.org/0000-0003-2024-3299)
- Ankush Gaikwad
- Priti Gajbe
Institutions
- Emcure Pharmaceuticals (India) (IN)
- Sir Ganga Ram Hospital (IN)
- Bangalore Diabetes Centre (IN)
- Mysore Medical College (IN)
- Institute of Mental Health and Hospital (IN)
Publication Details
- Journal
- World Journal of Nephrology
- Published
- 2025-04-08
- DOI
- https://doi.org/10.5527/wjn.v14.i2.100117
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00